SCHEMBL11029448

SCHEMBL11029448

COC(=O)c1ccc(NC(=O)n2ccc(Nc3nc4ccccn4c3-c3cc(N)nc(C)n3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 16/20 0.53
PIK3CA P42336 15/20 0.53
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
PDGFRA P16234 1/20 0.39
PRKACA P17612 1/20 0.39
LTK P29376 1/20 0.39
GRK5 P34947 1/20 0.39
KDR P35968 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CDK8 P49336 1/20 0.39
CLK2 P49760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL753784 0.93 PIK3CA (0.47) MTORPIK3CADAPK3JAK2PRKD3
SCHEMBL16161710 0.92 MTOR (0.54) MTORPIK3CAPIK3CBCCNE1CDK2
SCHEMBL11031207 0.91 MTOR (0.53) MTORPIK3CA
SCHEMBL11031097 0.91 MTOR (0.58) MTORPIK3CAPIK3CBCCNE1CDK2
SCHEMBL16161620 0.87 MTOR (0.52) MTORPIK3CAPIK3CBCCNE1CDK2
SCHEMBL11026350 0.85 MTOR (0.58) MTORPIK3CADAPK3JAK2PRKD3
SCHEMBL11030435 0.85 MTOR (0.53) MTORPIK3CADAPK3JAK2PRKD3
SCHEMBL11026844 0.85 MTOR (0.56) MTORPIK3CAKDM4EPIK3CBCCNE1
SCHEMBL16161680 0.83 MTOR (0.60) MTORPIK3CAPIK3CBCCNE1CDK2
SCHEMBL11029456 0.83 MTOR (0.58) MTORPIK3CADAPK3JAK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD MTOR 21/4885PIK3CA 1/4885DAPK3 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.